Treatment of depression in the medically III

Journal of Clinical Psychopharmacology

Volumn 25, Issue 4 SUPPL. 1, 2005, Pages

  Krishnan, K Ranga Rama ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DRUG METABOLITE; FLUOXETINE; IMIPRAMINE; NORSERTRALINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BEHAVIOR THERAPY; BLEEDING; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISABILITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; MAJOR DEPRESSION; MORTALITY; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PATHOLOGICAL CRYING; PRIORITY JOURNAL; PROBLEM SOLVING; REMISSION; SIDE EFFECT; STROKE; TACHYCARDIA; THROMBOCYTE ANOMALY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CEREBROVASCULAR ACCIDENT; COGNITIVE THERAPY; CORONARY ARTERIOSCLEROSIS; DEMENTIA; DEPRESSIVE DISORDER; DIABETES MELLITUS; HUMANS; PARKINSON DISEASE;

EID: 23044495546     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162808.92194.2a     Document Type: Conference Paper

References (44)

1. Kurzthaler I, Hotter A, Miller C, et al. Risk profile of SSRIs in elderly depressive patients with co-morbid physical illness. Pharmacopsychiatry. 2001;34(3):114-118.
2. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216-226.
3. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54(3):208-215.
4. Unutzer J, Katon W, Williams JW Jr, et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. Med Care. 2001;39(8):785-799.
5. Krishnan KR, Doraiswamy PM, Clary CM. Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(2):347-361.
6. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54(3):317-329.
7. Katon W, Von Korff M, Lin E, et al. Population-based care of depression: effective disease management strategies to decrease prevalence. Gen Hosp Psychiatry. 1997;19(3):169-178.
8. Katon W, von Korff M, Ciechanowski P, et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care. 2004;27(4):914-920.
9. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001;13(1):31-41.
10. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61(10):1042-1049.
11. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992;52(5):547-552.
12. Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;129(8):613-621.
13. Lustman PJ, Freedland KE, Griffith LS, et al. Predicting response to cognitive behavior therapy of depression in type 2 diabetes. Gen Hosp Psychiatry. 1998;20(5):302-306.
14. Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry. 2003; 54(3):241-247.
15. Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999;156(7):1024-1028.
16. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279(4):287-291.
17. Carney RM, Freedland KE, Stein PK, et al. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med. 2000;62(5):639-647.
18. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54(3):227-240.
19. Shapiro PA, Lesperance F, Frasure-Smith N, et al. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J. 1999;137(6):1100-1106.
20. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43(5):453-462.
21. Enhancing Recovery in Coronary Heart Disease (ENRICHD Investigators) study intervention: rationale and design. Psychosom Med. 2001; 63(5):747-755.
22. Carney RM, Blumenthal JA, Freedland KE, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med. 2004; 66(4):466-474.
23. Frasure-Smith N, Lesperance F, Prince RH, et al. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet. 1997;350(9076):473-479.
24. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry. 2003;54(3):376-387.
25. Sturm JW, Donnan GA, Dewey HM, et al. Determinants of handicap after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2004;35(3):715-720.
26. Dam M, Tonin P, DeBoni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27(7):1211-1214.
27. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1984;1(8372): 297-300.
28. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157(3):351-359.
29. Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke. 2000;31(7):1482-1486.
30. Andersen G, Vestergaard K, Lauritzen LU. Effective treatment of depression following apoplexy with citalopram. Ugeskr Laeger. 1995; 157(14):2000-2003.
31. Muller U, Murai T, Bauer-Wittmund T, et al. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj. 1999;13(10):805-811.
32. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet. 1993;342(8875):837-839.
33. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708-714.
34. Reifler BV, Ten L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989;146(1):45-49.
35. Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997;38(3):246-252.
36. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13(2):100-108.
37. Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord. 2004;17(1-2):55-64.
38. Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry. 2000;157 (10):1686-1689.
39. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737-746.
40. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894-901.
41. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86(2): 138-145.
42. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002;17(1):60-67.
43. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24(4):221-227.
44. Menza M, Marin H, Kaufman K, et al. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004;16(3):315-319.